Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer

Although anti–programmed death‐1 (PD‐1)/programmed death ligand 1 (PD‐L1) immunotherapy has achieved great success in some cancers, most colorectal cancer (CRC) patients remain unresponsive. Therefore, further clarification of the underlying mechanisms is needed to improve the therapy. In this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chaoyan, Weng, Menghan, Xia, Shuli, Zhang, Min, Chen, Chaoyi, Tang, Jinlong, Huang, Dan, Yu, Hongfei, Sun, Wenjie, Zhang, Honghe, Lai, Maode
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Cell, Molecular, and Stem Cell Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780007/
https://www.ncbi.nlm.nih.gov/pubmed/33058325
http://dx.doi.org/10.1111/cas.14690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780007/
https://www.ncbi.nlm.nih.gov/pubmed/33058325
http://dx.doi.org/10.1111/cas.14690

Ejemplares similares